Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 37, 2014, Pages 13439-13444

  Hu, Haitao ^a,b   Eller, Michael A ^a,b   Zafar, Shah ^a,b   Zhou, Yu ^c   Gu, Mengnan ^d   Wei, Zhi ^d   Currier, Jeffrey R ^a   Marovich, Mary A ^e   Kibuuka, Hannah N ^f   Bailer, Robert T ^e   Koup, Richard A ^e   Robb, Merlin L ^a,b   Michael, Nelson L ^a   Kim, Jerome H ^a   Ratto Kim, Silvia ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University Heights   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Makerere University   (Uganda)

Author keywords

AIDS; Antigen specific CD4 T cells; Viral vectors

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 17; INTERLEUKIN 2;

ADENOVIRIDAE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOMEGALOVIRUS; DISEASE PREDISPOSITION; GENETIC RECOMBINATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFLAMMATION; INTESTINE MUCOSA; NORMAL HUMAN; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHENOTYPE; SPECIES DIFFERENCE; TH17 CELL; VIROLOGY;

ADENOVIRIDAE; AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; DISEASE SUSCEPTIBILITY; HEALTHY VOLUNTEERS; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-2; INTESTINAL MUCOSA; PHENOTYPE; RECOMBINATION, GENETIC; SPECIES SPECIFICITY; TH17 CELLS;

EID: 84907190281     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1400446111     Document Type: Article

References (30)

1. Shiver JW, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415(6869):331-335.
2. Buchbinder SP, et al.; Step Study Protocol Team (2008) Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653):1881-1893.
3. Gray GE, et al.; HVTN 503/Phambili Study Team (2011) Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11(7):507-515.
4. Hammer SM, et al.; HVTN 505 Study Team (2013) Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369(22):2083-2092.
5. Duerr A, et al.; Step/HVTN 504 Study Team (2012) Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206(2):258-266.
6. Qureshi H, et al. (2012) Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 86(4):2239-2250.
7. Li Q, et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458(7241):1034-1038.
8. Hu H, et al. (2013) Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection. Blood 121(7):1136-1144.
9. Geldmacher C, et al. (2010) Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med 207(13):2869-2881.
10. Hansen SG, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473(7348):523-527.
11. Eller MA, et al. (2007) Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 25(45): 7737-7742.
12. Brenchley JM, et al. (2004) CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200(6):749-759.
13. Arthos J, et al. (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9(3):301-309.
14. Flynn NM, et al.; rgp120 HIV Vaccine Study Group (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191(5):654-665.
15. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361(23):2209-2220.
16. Benlahrech A, et al. (2009) Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 106(47):19940-19945.
17. National Institute of Allergy and Infectious Diseases (2013) Mini-Summit on Adenovirus Platforms for HIV Vaccines (National Institutes of Health, Bethesda, MD).
18. Masek-Hammerman K, et al. (2010) Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol 84(19):9810-9816.
19. Frahm N, et al. (2012) Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122(1):359-367.
20. Barouch DH (2010) Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5(5):386-390.
21. Hoke CH, Jr, Snyder CE, Jr (2013) History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. Vaccine 31(12):1623-1632.
22. Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP (2014) Immunology. Immune activation with HIV vaccines. Science 344(6179):49-51.
23. Staprans SI, et al. (2004) Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 101(35):13026-13031.
24. Brenchley JM, et al. (2008) Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112(7):2826-2835.
25. Garnett CT, Erdman D, Xu W, Gooding LR (2002) Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 76(21):10608-10616.
26. Kaur G, et al. (2007) Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection. Virology 369(1):214-225.
27. Guan Y, Abdelwahab S, Kamin-Lewis R, DeVico AL, Lewis GK (2008) Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands. PLoS ONE 3(10):e3481.
28. Casazza JP, et al. (2009) Autocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infection. PLoS Pathog 5(10):e1000646.
29. Currier JR, et al. (2010) Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS ONE 5(11):e13983.
30. Paris R, et al. (2014) Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors. Clin Vaccine Immunol 21(5):783-786.